Wellness products company Nature’s Sunshine (NASDAQ: NATR) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 8.5% year on year to $122.9 million. The company expects the full year’s revenue to be around $507.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.30 per share was 46.3% above analysts’ consensus estimates.
Is now the time to buy Nature's Sunshine? Find out by accessing our full research report, it’s free.
Nature's Sunshine (NATR) Q1 CY2026 Highlights:
- Revenue: $122.9 million vs analyst estimates of $122.2 million (8.5% year-on-year growth, 0.6% beat)
- Adjusted EPS: $0.30 vs analyst estimates of $0.21 (46.3% beat)
- Adjusted EBITDA: $14.58 million vs analyst estimates of $10.76 million (11.9% margin, 35.5% beat)
- The company reconfirmed its revenue guidance for the full year of $507.5 million at the midpoint
- EBITDA guidance for the full year is $52 million at the midpoint, in line with analyst expectations
- Operating Margin: 7.8%, up from 5.4% in the same quarter last year
- Free Cash Flow was -$4.33 million, down from $1.50 million in the same quarter last year
- Market Capitalization: $459.3 million
“We delivered a strong start to 2026, reflecting continued momentum across our key strategic initiatives,” said Ken Romanzi, CEO of Nature’s Sunshine.
Company Overview
Started on a kitchen table in Utah, Nature’s Sunshine (NASDAQ: NATR) manufactures and sells nutritional and personal care products.
Revenue Growth
A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years.
With $489.8 million in revenue over the past 12 months, Nature's Sunshine is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.
As you can see below, Nature's Sunshine’s 5.3% annualized revenue growth over the last three years was tepid. This shows it failed to generate demand in any major way and is a rough starting point for our analysis.
This quarter, Nature's Sunshine reported year-on-year revenue growth of 8.5%, and its $122.9 million of revenue exceeded Wall Street’s estimates by 0.6%.
Looking ahead, sell-side analysts expect revenue to grow 5% over the next 12 months, similar to its three-year rate. This projection doesn't excite us and implies its newer products will not lead to better top-line performance yet.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
Cash Is King
Although earnings are undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills.
Nature's Sunshine has shown mediocre cash profitability relative to peers over the last two years, giving the company fewer opportunities to return capital to shareholders. Its free cash flow margin averaged 4.3%, below what we’d expect for a consumer staples business.
Nature's Sunshine burned through $4.33 million of cash in Q1, equivalent to a negative 3.5% margin. The company’s cash flow turned negative after being positive in the same quarter last year. This warrants extra attention because consumer staples companies typically produce more consistent and defensive performance.
Key Takeaways from Nature's Sunshine’s Q1 Results
It was good to see Nature's Sunshine beat analysts’ EPS expectations this quarter. We were also excited its EBITDA outperformed Wall Street’s estimates by a wide margin. Overall, we think this was still a solid quarter with some key areas of upside. The stock remained flat at $24.47 immediately after reporting.
Should you buy the stock or not? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).
